MedPath

Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel)

Phase 4
Conditions
Acne Papulopustulosa
Interventions
Radiation: VIS and wIRA
Drug: Adapalen
Registration Number
NCT00237978
Lead Sponsor
Technische Universität Dresden
Brief Summary

The aim of the study is to investigate the effectivity of visible light in combination with waterfiltered infrared in treating acne papulopustulosa. The reduction of inflammatory and non-inflammatory lesions within 8 weeks will be measured and compared with the standard treatment with Adapalene.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Mild to moderate acne papulopustulosa according to Burton Scale Stage 3 to 4
  • At least 5 inflammatory and 5 non-inflammatory lesions in the face
  • Age >= 14 years
Exclusion Criteria
  • pregnant and nursing women
  • Antiandrogen therapy
  • therapy with antibiotics within the last 4 weeks
  • therapy with retinoids within the last 6 months
  • natural or artificial UV-therapy within the last 4 weeks
  • severe acne papulopustulosa according to Burton Scale 5 or 6
  • Severe systemic condition
  • Secondary acne

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1VIS and wIRAVIS and wIRA
2AdapalenVIS, wIRA and Adapalen
2VIS and wIRAVIS, wIRA and Adapalen
3AdapalenAdapalen
Primary Outcome Measures
NameTimeMethod
reduction of inflammatory and non-inflammatory lesions within 8 weeks after start of therapy
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

🇩🇪

Dresden, Sachsen, Germany

© Copyright 2025. All Rights Reserved by MedPath